Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16174355 | 0.90 | SCN9A (0.82) | SCN9AMAPK14CYP3A4MAPTPTGER4 | |
| SCHEMBL14920084 | 0.86 | SCN9A (0.76) | SCN9AMAPK14CYP3A4MAPTPTGER4 | |
| SCHEMBL16172462 | 0.85 | SCN9A (0.75) | SCN9AMAPK14CYP3A4MAPTL3MBTL1 | |
| SCHEMBL14920244 | 0.82 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16172524 | 0.82 | SCN9A (0.69) | SCN9AMAPK14CYP3A4MAPTPTGER4 | |
| SCHEMBL14921893 | 0.81 | SCN9A (0.74) | SCN9AMAPK14CYP3A4LMNA | |
| SCHEMBL16172469 | 0.80 | SCN9A (0.67) | SCN9APOLB | |
| SCHEMBL14919913 | 0.78 | SCN9A (0.74) | SCN9A | |
| SCHEMBL16172516 | 0.78 | SCN9A (0.64) | SCN9AMAPK14CYP3A4MAPTPTGER4 | |
| SCHEMBL16172474 | 0.77 | SCN9A (0.63) | SCN9AMAPK14CYP3A4MAPTPTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-9388137-B2 | Quaternized amines as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2016-07-12 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2014-10-16 | — | — | US | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064884-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. (US) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309228-A1 | QUATERNIZED AMINES AS SODIUM CHANNEL BLOCKERS | CACNA1A, SCN1B, SCN1A | SCN9A 23/4885MAPK14 3352/4885CYP3A4 1275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.